H1299 and A549 NSCLC cells were obtained from American Type Culture Collection
(ATCC, Manassas, USA) and cultivated in RPMI-1640 medium (Invitrogen) with 10%
fetal calf serum (FCS, Biosera, Boussens, France) as reported.18 (link) Human bronchial 16HBE cell line (Procell, Wuhan, China) was used as a
control of non-tumor cells and propagated using standard protocols provided by
Procell. 293 T cells (ATCC) were cultivated in maintain medium provided by ATCC
for dual-luciferase reporter assays.
DTX-resistant NSCLC cells (A549/DTX and H1299/DTX) were established in our
laboratory by treating A549 and H1299 cells with gradually increasing
concentrations of DTX (Sigma-Aldrich, Steinheim, Germany; starting from 20 ng/L
and progressively increasing the concentration up to 10 µg/L) more than 9 months
until they acquired the ability to grow in the presence of DTX at the same rate
as parental cells in the absence of the drug. To maintain the resistance
phenotype, additional 10 µg/L of DTX was used in the cell medium.
(ATCC, Manassas, USA) and cultivated in RPMI-1640 medium (Invitrogen) with 10%
fetal calf serum (FCS, Biosera, Boussens, France) as reported.18 (link) Human bronchial 16HBE cell line (Procell, Wuhan, China) was used as a
control of non-tumor cells and propagated using standard protocols provided by
Procell. 293 T cells (ATCC) were cultivated in maintain medium provided by ATCC
for dual-luciferase reporter assays.
DTX-resistant NSCLC cells (A549/DTX and H1299/DTX) were established in our
laboratory by treating A549 and H1299 cells with gradually increasing
concentrations of DTX (Sigma-Aldrich, Steinheim, Germany; starting from 20 ng/L
and progressively increasing the concentration up to 10 µg/L) more than 9 months
until they acquired the ability to grow in the presence of DTX at the same rate
as parental cells in the absence of the drug. To maintain the resistance
phenotype, additional 10 µg/L of DTX was used in the cell medium.
